| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
None (excipient). Lipid 29 is an ionizable amino lipid with a pKa of 6.91, which is neutral at physiological pH (7.4) and becomes positively charged in acidic endosomes (pH 5-6), enabling nucleic acid encapsulation and facilitating endosomal escape.
|
|---|---|
| ln Vitro |
Lipid 29 stabilizes LNP structure through hydrogen bonding and pi-pi stacking interactions (contributed by its amino headgroup and hydrophobic tails). In vitro, Lipid 29 LNPs efficiently encapsulate mRNA (>90%) and deliver it to cells, resulting in high transfection efficiency (e.g., EPO protein expression in HepG2 or HEK293 cells). Lipid 29 LNPs show low cytotoxicity.
|
| ln Vivo |
In vivo, intravenous administration of Lipid 29 LNPs encapsulating human EPO mRNA to mice leads to robust EPO protein expression in the circulation, demonstrating efficacy as an mRNA delivery vehicle. The pKa of 6.91 is optimal for endosomal escape, contributing to high potency. Lipid 29 LNPs are primarily hepatotropic, accumulating in the liver after i.v. administration.
|
| Enzyme Assay |
Lipid 29 (C₅2H₉₇N3O₆, MW 860.34) is an oil soluble in DMSO (100 mg/mL). For LNP preparation, Lipid 29 is dissolved in ethanol and mixed with helper lipids (e.g., DSPC, cholesterol, PEG2000-DMG or PEG2000-DSPE) at optimized molar ratios (e.g., 50:10:38.5:1.5). This mixture is combined with an acidic aqueous buffer (e.g., 25-50 mM sodium acetate, pH 4) containing mRNA via microfluidic mixing at a flow rate ratio of 3:1 (aqueous:ethanol). LNPs form spontaneously (size ∼80 nm). The pH is raised to 7.4 during dialysis, and pKa is confirmed (∼6.91). Encapsulation efficiency (>90%) is measured by Ribogreen assay.
|
| Cell Assay |
For in vitro studies, Lipid 29 LNPs are diluted in serum-free DMEM. HEK293 or HepG2 cells are seeded in 96-well plates (1-2×10⁴ cells/well) and treated with LNPs at mRNA doses of 0.01-1 ug/well. After 4-6 h, medium is replaced. Luciferase or EPO protein levels are measured 24 h post-transfection by luminescence or ELISA. Cellular uptake is assessed by flow cytometry using fluorescently labeled mRNA. Cytotoxicity is evaluated by MTT assays; Lipid 29 LNPs show cell viability >90% at effective doses.
|
| Animal Protocol |
For in vivo studies, Lipid 29 LNPs encapsulating human EPO mRNA or luciferase mRNA are administered intravenously via the tail vein to female BALB/c or C57BL/6 mice (6-8 weeks old) at mRNA doses of 0.1-1 mg/kg. Blood samples are collected at 2, 4, 8, 12, and 24 h post-dose via retro-orbital bleeding or tail vein snip. Serum EPO levels are quantified by human EPO ELISA. For luciferase: in vivo bioluminescence imaging is performed 6-24 h post-dose after D-luciferin injection. Mice are euthanized 24-72 h post-dose; tissues (liver, spleen, lung, kidney) are harvested for ex vivo imaging, qRT-PCR to quantify mRNA distribution, and H&E histology.
|
| ADME/Pharmacokinetics |
Following i.v. administration, Lipid 29 LNPs have a circulation half-life of ∼2-4 h. LNPs accumulate primarily in the liver (∼50-70% of injected dose) and spleen (∼10-20%). The ionizable amino lipid has a calculated logP consistent with hepatocyte uptake via apolipoprotein E (ApoE)-mediated endocytosis. Metabolism likely involves hydrolysis of ester linkages, releasing fatty acids and amino alcohol fragments that are cleared via biliary and renal routes. mRNA is released in the cytosol and translated into protein (e.g., EPO).
|
| Toxicity/Toxicokinetics |
Lipid 29 LNPs are generally well-tolerated at mRNA doses ≤1 mg/kg. Mild, transient elevation of liver enzymes (ALT/AST) may occur, returning to baseline within 48 h. No significant histopathological changes in the liver or other organs have been reported. Inflammatory cytokine levels (IL-6, TNF-alpha) may be transiently elevated. Lipid 29 is not considered toxic at therapeutic doses; however, comprehensive toxicity studies (e.g., repeat-dose, genotoxicity) are not publicly available.
|
| References | |
| Additional Infomation |
Lipid 29 (CAS 2244716-55-8, C₅2H₉₇N3O₆, MW 860.34) has >99% purity and is an oil. Storage at -20degC as a powder (stable for 3 years) and at -80degC in solvent (stable for 6 months). Lipid 29 is for research use only; no clinical trials or regulatory approvals have been reported. It is a synthetic amphiphilic compound engineered to replicate the self-assembling behavior of natural membrane lipids, offering experimental control and structural uniformity.
|
| Molecular Formula |
C52H97N3O6
|
|---|---|
| Molecular Weight |
860.34
|
| Exact Mass |
859.737
|
| CAS # |
2244716-55-8
|
| PubChem CID |
135329651
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
17.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
48
|
| Heavy Atom Count |
61
|
| Complexity |
1130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(C(=O)C1=O)NC
|
| InChi Key |
BADFTFAWFNGVTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C52H97N3O6/c1-6-10-13-16-21-28-36-45(9-4)60-47(56)39-31-24-19-26-33-42-55(44-35-41-54-50-49(53-5)51(58)52(50)59)43-34-27-20-25-32-40-48(57)61-46(37-29-22-17-14-11-7-2)38-30-23-18-15-12-8-3/h45-46,53-54H,6-44H2,1-5H3
|
| Chemical Name |
undecan-3-yl 8-[(8-heptadecan-9-yloxy-8-oxooctyl)-[3-[[2-(methylamino)-3,4-dioxocyclobuten-1-yl]amino]propyl]amino]octanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1623 mL | 5.8117 mL | 11.6233 mL | |
| 5 mM | 0.2325 mL | 1.1623 mL | 2.3247 mL | |
| 10 mM | 0.1162 mL | 0.5812 mL | 1.1623 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
